TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL ATHEROSCLEROSIS MARKET, BY STAGE
6.1. Overview
6.2. Endothelial Damage and Immune Response
6.3. Fatty Streak
6.4. Plaque Growth
6.5. Plaque Rupture
7. GLOBAL ATHEROSCLEROSIS MARKET, BY DIAGNOSIS
7.1. Overview
7.2. Ankle-brachial Index (ABI)
7.3. Doppler Ultrasound
7.4. Echocardiogram
7.5. Electrocardiogram (ECG)
7.6. Blood Tests
7.7. Others
8. GLOBAL ATHEROSCLEROSIS MARKET, BY TREATMENT
8.1. Overview
8.2. Medication
8.3. Surgery
9. GLOBAL ATHEROSCLEROSIS MARKET, BY END-USER
9.1. Overview
9.2. Hospitals
9.3. Specialty Clinics
9.4. Homecare
9.5. Others
10. GLOBAL ATHEROSCLEROSIS MARKET, BY REGION
10.1. Overview
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. France
10.2.3. UK
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. South Korea
10.3.5. Australia
10.3.6. Rest of Asia-Pacific
10.4. Rest of the World
10.4.1. Middle East
10.4.2. Africa
10.4.3. Latin America
11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market Share Analysis
11.4. Major Growth Strategy in the Global Atherosclerosis Market,
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Global Atherosclerosis Market,
11.7. Key developments and Growth Strategies
11.7.1. New Product Launch/Service Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales & Operating Income, 2022
11.8.2. Major Players R&D Expenditure. 2022
12. COMPANY PROFILES
12.1. F. Hoffmann-La Roche Ltd. (Switzerland)
12.1.1. Company Overview
12.1.2. Financial Overview
12.1.3. Products Offered
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. Teva Pharmaceutical Industries Ltd. (Ireland)
12.2.1. Company Overview
12.2.2. Financial Overview
12.2.3. Products Offered
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.2.6. Key Strategies
12.3. Sanofi (France)
12.3.1. Company Overview
12.3.2. Financial Overview
12.3.3. Products Offered
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies
12.4. ALLERGAN (IRELAND)
12.4.1. Company Overview
12.4.2. Financial Overview
12.4.3. Products Offered
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies
12.5. ASTRAZENECA (U.K.)
12.5.1. Company Overview
12.5.2. Financial Overview
12.5.3. Products Offered
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies
12.6. Boehringer Ingelheim International GmbH. (Germany)
12.6.1. Company Overview
12.6.2. Financial Overview
12.6.3. Products Offered
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies
12.7. NOVARTIS AG (SWITZERLAND)
12.7.1. Company Overview
12.7.2. Financial Overview
12.7.3. Products Offered
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies
12.8. Pfizer Inc. (U.S.)
12.8.1. Company Overview
12.8.2. Financial Overview
12.8.3. Products Offered
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.8.6. Key Strategies
12.9. GlaxoSmithKline plc (U.K.)
12.9.1. Company Overview
12.9.2. Financial Overview
12.9.3. Products Offered
12.9.4. Key Developments
12.9.5. SWOT Analysis
12.9.6. Key Strategies
12.10. Hikma Pharmaceuticals PLC (U.K.)
12.10.1. Company Overview
12.10.2. Financial Overview
12.10.3. Products Offered
12.10.4. Key Developments
12.10.5. SWOT Analysis
12.10.6. Key Strategies
12.11. Bayer AG (Germany)
12.11.1. Company Overview
12.11.2. Financial Overview
12.11.3. Products Offered
12.11.4. Key Developments
12.11.5. SWOT Analysis
12.11.6. Key Strategies
12.12. Dr. Reddy's Laboratories Ltd. (India)
12.12.1. Company Overview
12.12.2. Financial Overview
12.12.3. Products Offered
12.12.4. Key Developments
12.12.5. SWOT Analysis
12.12.6. Key Strategies
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL ATHEROSCLEROSIS MARKET, SYNOPSIS, 2018-2032
TABLE 2 GLOBAL ATHEROSCLEROSIS MARKET, ESTIMATES & FORECAST, 2018-2032 (USD BILLION)
TABLE 3 GLOBAL ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 4 GLOBAL ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 5 GLOBAL ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 6 GLOBAL ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 7 NORTH AMERICA: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 8 NORTH AMERICA: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 9 NORTH AMERICA: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 10 NORTH AMERICA: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 11 US: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 12 US: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 13 US: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 14 US: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 15 CANADA: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 16 CANADA: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 17 CANADA: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 18 CANADA: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 1 EUROPE: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 2 EUROPE: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 3 EUROPE: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 4 EUROPE: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 5 GERMANY: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 6 GERMANY: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 7 GERMANY: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 8 GERMANY: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 9 FRANCE: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 10 FRANCE: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 11 FRANCE: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 12 FRANCE: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 13 ITALY: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 14 ITALY: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 15 ITALY: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 16 ITALY: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 17 SPAIN: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 18 SPAIN: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 19 SPAIN: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 20 SPAIN: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 21 UK: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 22 UK: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 23 UK: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 24 UK: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 25 REST OF EUROPE: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 26 REST OF EUROPE: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 27 REST OF EUROPE: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 28 REST OF EUROPE: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 29 ASIA-PACIFIC: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 30 ASIA-PACIFIC: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 31 ASIA-PACIFIC: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 32 ASIA-PACIFIC: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 33 JAPAN: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 34 JAPAN: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 35 JAPAN: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 36 JAPAN: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 37 CHINA: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 38 CHINA: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 39 CHINA: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 40 CHINA: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 41 INDIA: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 42 INDIA: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 43 INDIA: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 44 INDIA: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 45 AUSTRALIA: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 46 AUSTRALIA: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 47 AUSTRALIA: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 48 AUSTRALIA: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 49 SOUTH KOREA: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 50 SOUTH KOREA: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 51 SOUTH KOREA: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 52 SOUTH KOREA: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 53 REST OF ASIA-PACIFIC: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 54 REST OF ASIA-PACIFIC: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 55 REST OF ASIA-PACIFIC: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 56 REST OF ASIA-PACIFIC: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 57 REST OF THE WORLD: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 58 REST OF THE WORLD: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 59 REST OF THE WORLD: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 60 REST OF THE WORLD: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 61 MIDDLE EAST: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 62 MIDDLE EAST: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 63 MIDDLE EAST: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 64 MIDDLE EAST: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 65 AFRICA: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 66 AFRICA: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 67 AFRICA: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 68 AFRICA: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
TABLE 69 LATIN AMERICA: ATHEROSCLEROSIS MARKET, BY STAGE, 2018-2032 (USD BILLION)
TABLE 70 LATIN AMERICA: ATHEROSCLEROSIS MARKET, BY DIAGNOSIS, 2018-2032 (USD BILLION)
TABLE 71 LATIN AMERICA: ATHEROSCLEROSIS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 72 LATIN AMERICA: ATHEROSCLEROSIS MARKET, BY END-USER, 2018-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ATHEROSCLEROSIS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ATHEROSCLEROSIS MARKET
FIGURE 4 GLOBAL ATHEROSCLEROSIS MARKET, SHARE (%), BY STAGE, 2022
FIGURE 5 GLOBAL ATHEROSCLEROSIS MARKET, SHARE (%), BY DIAGNOSIS, 2022
FIGURE 6 GLOBAL ATHEROSCLEROSIS MARKET, SHARE (%), BY TREATMENT, 2022
FIGURE 7 GLOBAL ATHEROSCLEROSIS MARKET, SHARE (%), BY END-USER, 2022
FIGURE 8 GLOBAL ATHEROSCLEROSIS MARKET, SHARE (%), BY REGION, 2022
FIGURE 9 NORTH AMERICA: ATHEROSCLEROSIS MARKET, SHARE (%), BY REGION, 2022
FIGURE 10 EUROPE: ATHEROSCLEROSIS MARKET, SHARE (%), BY REGION, 2022
FIGURE 11 ASIA-PACIFIC: ATHEROSCLEROSIS MARKET, SHARE (%), BY REGION, 2022
FIGURE 12 REST OF THE WORLD: ATHEROSCLEROSIS MARKET, SHARE (%), BY REGION, 2022
FIGURE 13 GLOBAL ATHEROSCLEROSIS MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 14 F. HOFFMANN-LA ROCHE LTD. (SWITZERLAND): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 F. HOFFMANN-LA ROCHE LTD. (SWITZERLAND): SWOT ANALYSIS
FIGURE 16 TEVA PHARMACEUTICAL INDUSTRIES LTD. (IRELAND): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 TEVA PHARMACEUTICAL INDUSTRIES LTD. (IRELAND): SWOT ANALYSIS
FIGURE 18 SANOFI (FRANCE): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 SANOFI (FRANCE): SWOT ANALYSIS
FIGURE 20 ALLERGAN (IRELAND): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 ALLERGAN (IRELAND): SWOT ANALYSIS
FIGURE 22 ASTRAZENECA (U.K.).: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 ASTRAZENECA (U.K.).: SWOT ANALYSIS
FIGURE 24 BOEHRINGER INGELHEIM INTERNATIONAL GMBH. (GERMANY): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 BOEHRINGER INGELHEIM INTERNATIONAL GMBH. (GERMANY): SWOT ANALYSIS
FIGURE 26 NOVARTIS AG (SWITZERLAND): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 NOVARTIS AG (SWITZERLAND): SWOT ANALYSIS
FIGURE 28 PFIZER INC. (U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 PFIZER INC. (U.S.): SWOT ANALYSIS
FIGURE 30 GLAXOSMITHKLINE PLC (U.K.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 GLAXOSMITHKLINE PLC (U.K.): SWOT ANALYSIS
FIGURE 32 HIKMA PHARMACEUTICALS PLC (U.K.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 HIKMA PHARMACEUTICALS PLC (U.K.): SWOT ANALYSIS
FIGURE 34 BAYER AG (GERMANY): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 BAYER AG (GERMANY): SWOT ANALYSIS
FIGURE 36 DR. REDDY'S LABORATORIES LTD. (INDIA): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 DR. REDDY'S LABORATORIES LTD. (INDIA): SWOT ANALYSIS
